Lafayette, Richard

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Floege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 263

Atrasentan in Patients with IgA Nephropathy

Heerspink, H. J. L., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Lodha, A., Gray, T., Wang, Y., et al. (2025) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 142

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Perkovic, V., Trimarchi, H., Tesar, V., Lafayette, R., Wong, M. G., Barratt, J., Suzuki, Y., Liew, A., Zhang, H., Carroll, K., et al. (2026) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 90

Individualised treatment effects of corticosteroids in IgA nephropathy

Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 2

Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis

Barratt, J., Brenner, R. M., Barbour, S. J., Campbell, K. N., Doan, T., Eren, N., Floege, J., Fordyce, M. W., Jha, V., Khawaja, Z., et al. (2026) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 1